Comparison of CD146 Positive and Negative Mesenchymal Stem Cells in Improving Premature Ovarian Failure

    June 2022 in “ Stem Cell Research & Therapy ”
    Lin Zhang, Yang Sun, Xiaoxu Zhang, Yubin Liu, Huiyan Sun, Chu-Tse Wu, Fengjun Xiao, Lisheng Wang
    Studysummary This study found that umbilical cord-derived CD146+ MSCs showed a stronger ability to improve ovarian function and modulate immune responses in a mouse model of premature ovarian failure compared to CD146- MSCs, though both subpopulations effectively repaired reproductive ability. Our plain-language summary of this paper — not a Tressless recommendation.
    The study compared the therapeutic efficacy of CD146 + and CD146 - mesenchymal stem cells (MSCs) in treating premature ovarian failure (POF) using a mouse model. Both MSC types improved ovarian function, increased ovarian follicles, and restored hormone levels, but CD146 + MSCs demonstrated superior proliferation, immune modulation, and cytokine secretion. CD146 + MSCs were more effective in reversing lymphocyte changes and persisted longer in vivo, suggesting better immune regulation. The study concluded that while both MSC subpopulations were beneficial, CD146 + MSCs offered a slight advantage in efficacy, highlighting their potential for regenerative therapies in POF.
    Discuss this study in the Community →

    Research cited in this study

    2 / 2 results